Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2012. The report details a specific corporate action regarding a share repurchase executed on June 1, 2012, authorized by shareholders at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on share capital and treasury holdings.
- Shares Purchased: 2,000,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,432.5 pence per share; lowest price paid was 1,411.5 pence per share.
- Treasury Holdings (Settled): 448,757,927 shares (8.21% of total issued share capital).
- Treasury Holdings (Including Unsettled): 454,457,927 shares (9.06% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,016,181,436 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 2,000,000 shares on June 1, 2012. Consequently, the percentage of shares held in Treasury increased to 9.06% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares in issue (5,016,181,436) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the total treasury share count (454,457,927) to understand the dilution impact on voting rights.
- Note that the repurchase price range (1,411.5 to 1,432.5 pence) reflects the market value at the time of execution.